##### 





UNITED STATES SECURITIES AND
    EXCHANGE COMMISSIONWashington, DC
    20549
  Form 10-K
  þ

ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
    SECURITIES EXCHANGE ACT OF 1934For the fiscal year ended
    December 31, 2007o

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
    SECURITIES EXCHANGE ACT OF 1934For the transition
    period          to   Commission File Number
    001-33744
  TRANS1 INC.
 (Exact name of Registrant as
    specified in its charter)
  DELAWARE

33-0909022(State or other jurisdiction
    of
    incorporation or organization)

(I.R.S. employer
    identification no.)411 LANDMARK DRIVE,
    WILMINGTON, NC(Address of principal
    executive office)

28412-6303(Zip code)   (910) 332-1700
 (Registrants telephone
    number, including area code)
  o þ
  o þ
  þ o
  Regulation S-K Form 10-K Form 10-K. o
  Rule 12b-2
  Large accelerated
    filer o

Accelerated
    filer o

Non-accelerated
    filer þ(Do not check if a smaller
    reporting company)

Smaller reporting
    company o   Rule 12b-2 o þ
      DOCUMENTS
    INCORPORATED BY REFERENCE
  Form 10-K. Form 10-K.




---



##### 





TRANS1
    INC.
  FORM 10-K
    FOR THE FISCAL YEAR ENDED DECEMBER 31, 2007
 TABLE OF
    CONTENTS
  PART IItem 1.

Business


3Item 1A.

Risk Factors


18Item 1B.

Unresolved Staff Comments


36Item 2.

Properties


36Item 3.

Legal Proceedings


36Item 4.

Submission of Matters to a Vote of Security Holders


36PART IIItem 5.

Market for Registrants Common Equity, Related Stockholder
    Matters and Issuer Purchases of Equity Securities


37Item 6.

Selected Financial Data


40Item 7.

Managements Discussion and Analysis of Financial Condition
    and Results of Operations


41Item 7A.

Quantitative and Qualitative Disclosures About Market Risk


47Item 8.

Financial Statements and Supplementary Data


47Item 9.

Changes in and Disagreements With Accountants on Accounting and
    Financial Disclosure


47Item 9A.

Controls and Procedures


47Item 9B.

Other Information


48PART IIIItem 10.

Directors, Executive Officers and Corporate Governance


48Item 11.

Executive Compensation


48Item 12.

Security Ownership of Certain Beneficial Owners and Management
    and Related Stockholder Matters


48Item 13.

Certain Relationships and Related Transactions, and Director
    Independence


48Item 14.

Principal Accounting Fees and Services


48PART IVItem 15.

Exhibits, Financial Statement Schedules


49SIGNATURES


50Index to Financial Statements


72  2




---



##### 



Cautionary
    Note Regarding Forward-Looking Statements
      Item 1.
    Business  Overview
     3




---



##### 



28412-6303 (910) 332-1700. www.trans1.com
  Spine
    Anatomy
      Medical
    Conditions Affecting the Lower Lumbar Spine and Traditional
    Treatment Alternatives
     4




---



##### 



Anterior Lumbar Interbody Fusion, or ALIF.
  Posterior Lumbar Interbody Fusion, or PLIF.
  Transforaminal Lumbar Interbody Fusion, or
    TLIF.
  Extreme Lateral Interbody Fusion, or XLIF.
  360° Lumbar Fusion Procedure.
 5




---



##### 



Limitations
    of Traditional Lower Lumbar Spine Procedures
    
    Disruption to Soft Tissue and Support
    Structures.  Current lumbar fusion procedures
    require creating a pathway from the skin to the degenerative
    disc that is large enough to allow direct visualization and work
    by the surgeon. It is common to cut through healthy muscle or
    move critical organs, arteries, nerves and soft tissue, which
    can lead to bleeding, scarring, nerve damage and bowel
    disruption.
    Significant Blood Loss.  As a result of
    undergoing current lumbar fusion procedures, patients typically
    experience significant blood loss of between 100 and 1,400 cc of
    blood. As a result, it is common for patients to use the
    hospitals blood supply or donate units of their own blood
    before a lumbar fusion procedure to replenish any significant
    blood loss.
    Lengthy Operative Procedure Times.  We believe
    it is common for current lumbar fusion procedures to take
    between 90 minutes and 4 hours to complete. With some
    procedures a second surgeon may be required. Long procedure
    times increase the risks of complications and blood loss. Also,
    hospital and physician resources are consumed for lengthy
    periods of time, which can reduce productivity and increase
    costs.
    Lengthy Patient Hospital Stays.  Patients
    remain in the hospital for an average of three days following a
    lumbar fusion procedure which consumes hospital and physician
    resources.
    Significant Patient Recovery Time.  Patients
    require three to six months to recover and rehabilitate after
    undergoing a lumbar fusion procedure before resuming normal
    activities.
    Unresolved Patient Pain.  Patients may continue
    to experience lower back pain after undergoing lumbar fusion
    procedures even though x-rays show successful fusion has been
    achieved through the growth of new bone. We believe this may be
    caused by muscle dissection, implant irritation and scar tissue
    that develops around the site of the surgery.  Market
    Opportunity
       6




---



##### 



Our
    Solution
    S1/S2 tissue-protecting
    
    Least Invasive Approach Minimizes
    Complications.  Our AxiaLIF products are delivered
    using our TranS1 approach, which we believe is the least
    invasive approach to deliver fusion and motion preserving
    products to the L4/L5/S1 region. Procedures performed utilizing
    our TranS1 approach have been documented to have favorable
    clinical safety profiles with complication rates of
    approximately 1%.
    Ease of Use and Short Procedure Times.  We have
    received feedback from practicing surgeons that they can perform
    AxiaLIF procedures utilizing our TranS1 approach within 45 to 60
    minutes after they have performed just two to three surgeries.
    We believe that these short procedure times can result in
    reduced patient recovery times, decreased costs for the
    hospitals and increased productivity for the surgeons. We also
    believe the ease of use of our TranS1 approach enables reduced
    physician training as compared to alternative lower lumbar spine
    procedures.
    Low Blood Loss.  We believe the least invasive
    nature of our TranS1 approach results in the average patient
    losing approximately 25 to 125 cc of blood during an AxiaLIF or
    AxiaLIF 360° procedure, which correlates to reduced pain
    and faster recoveries. Given the associated low blood loss,
    patients generally do not need to donate blood prior to
    undergoing procedures that utilize our TranS1 approach.
    Short Patient Hospital Stays.  Patients
    typically stay only one night in the hospital after receiving a
    procedure performed using our TranS1 approach. In a small
    percentage of cases, patients are able to return home the same
    day.
    Reduction in Patient Pain.  We believe our
    TranS1 approach is effective at reducing lower back pain because
    surrounding soft tissue is not violated which prevents the
    creation of scar tissue, a leading cause of pain. 7




---



##### 



Our
    Strategy
    
    Establish our TranS1 Approach as a Standard of Care for Lower
    Lumbar Spine Surgery.  We believe patients
    commonly avoid back surgery due to its invasive nature and other
    drawbacks associated with current surgical treatment options. We
    expend significant resources promoting our TranS1 approach as
    the least invasive approach to lower back surgery and we believe
    the advantages of our TranS1 approach will enable our AxiaLIF
    products to become a standard of care for the lower lumbar
    region of the spine.
    Expand our Sales and Marketing Infrastructure to Drive
    Surgeon Adoption.  We intend to continue expending
    significant resources targeting spine surgeons through our sales
    and marketing efforts in the United States and internationally
    in order to drive the adoption of our TranS1 approach. We
    believe the ease of use, short procedure times, short hospital
    stays and reduction in patient pain will be compelling reasons
    for surgeon adoption of our technologies.
    Broaden the Applications of the TranS1
    Approach.  We believe that the applications for
    our TranS1 approach can be expanded beyond AxiaLIF and AxiaLIF
    360° to include multi-level fusion and multi-level motion
    preservation technologies. We are currently undertaking research
    and development activities with respect to these applications.
    Opportunistically Pursue Acquisitions of Complementary
    Businesses and Technologies.  In addition to
    building our internal product development efforts, we intend to
    selectively license or acquire complementary products and
    technologies that we believe will enable us to leverage our
    growing distribution platform.  Products
    AxiaLIF Lumbar Fusion Implants.
  AxiaLIF 360° Implants.
  TranS1 Access and Disc Preparation
    Instruments.
 8




---



##### 



Product
    Pipeline
    Percutaneous Nucleus Replacement.
  Partial Disc Replacement. ball-and-socket
    Sales and
    Marketing
       9




---



##### 



Surgeon
    Training
    Third-Party
    Reimbursement
    453/454/455
   10




---



##### 



side-by-side.
    Competition
   11




---



##### 




    improved outcomes for medical conditions affecting the lower
    lumbar spine;
    acceptance by spine surgeons;
    ease of use and reliability;
    product price and qualification for reimbursement;
    technical leadership and superiority;
    effective marketing and distribution; and
    speed to market.      Research
    and Development
      Manufacturing
    and Supply
     12




---



##### 



Patents
    and Proprietary Technology
    Patents
    
    our method for performing trans-sacral procedures in the spine,
    including diagnostic or therapeutic procedures, and trans-sacral
    introduction of instrumentation or implants;
    apparatus for conducting these procedures including access, disc
    preparation and implantation including the current TranS1
    instruments individually and in kit form; and
    implants for fusion and motion preservation in the spine.    Trademarks
  ® ® ® ® ®
 13




---



##### 



® ® ®
  Government
    Regulation
    
    product design and development;
    registration and listing;
    product testing (preclinical and clinical);
    product manufacturing;
    product labeling;
    product storage;
    premarket clearance or approval;
    advertising and promotion;
    product marketing, sales and distribution; and
    post-market surveillance, including reporting deaths or serious
    injuries related to products and certain product malfunctions.  FDAs
    Premarket Clearance and Approval Requirements
    510(k)
    Clearance Pathway
     14




---



##### 



and/or
  Premarket
    Approval Pathway
    in-depth
  Clinical
    Trials
   15




---



##### 



Pervasive
    and Continuing FDA Regulation
    
    quality system regulation, which requires manufacturers,
    including third-party contract manufacturers, to follow
    stringent design, testing, control, documentation, and other
    quality assurance controls, during all aspects of the
    manufacturing process;
    establishment registration and listing;
    labeling regulations, and FDA prohibitions against the promotion
    of products for uncleared or unapproved off-label
    uses;
    medical device reporting obligations, which require that
    manufacturers submit reports to the FDA if information
    reasonably suggests their device (i) may have caused or
    contributed to a death or serious injury, or
    (ii) malfunctioned and the device or a similar company
    device would likely cause or contribute to a death or serious
    injury if the malfunction were to recur; and
    other post-market surveillance requirements, which apply when
    necessary to protect the public health or to provide additional
    safety and effectiveness data for the device.      
    warning letters, fines, injunctions, consent decrees and civil
    penalties;
    repair, replacement, refunds, recall or seizure of our products;
    operating restrictions, partial suspension or total shutdown of
    production;
    refusing our request for 510(k) clearance or premarket approval
    of new products, new intended uses or other modifications to
    existing products;
    withdrawing or suspending premarket approvals that are already
    granted; and
    criminal prosecution.    Fraud
    and Abuse
   16




---



##### 



International
     17




---



##### 



Employees
    Item 1A.
    Risk
    Factors  Investing in our common stock involves a high degree of risk.
    You should carefully consider the following risk factors, as
    well as the other information contained in this report, before
    deciding whether to invest in shares of our common stock. If any
    of the following risks actually occur, our business, financial
    condition, operating results and prospects would suffer. In that
    case, the trading price of our common stock would likely decline
    and you might lose all or part of your investment in our common
    stock. The risks described below are not the only ones we face.
    Additional risks that we currently do not know about or that we
    currently believe to be immaterial may also impair our
    operations and business results.
  Risks
    Related to Our Business
  To be
    commercially successful, spine surgeons must accept that our
    products are a safe and effective alternative to existing
    surgical treatments of certain spine disorders.
    
    lack of long-term clinical data supporting additional patient
    benefits;
    lack of experience with our products;
    lack of evidence supporting cost savings of our procedure over
    existing surgical alternatives;
    perceived liability risks generally associated with the use of
    new products and procedures;
    training time required to use a new product; and
    availability of adequate coverage and reimbursement for
    hospitals and surgeons.    The
    efficacy of our products is not yet supported by long-term
    clinical data and may therefore prove to be less effective than
    initially thought.
   18




---



##### 



The
    demand for our products and the prices which customers and
    patients are willing to pay for our products depend upon the
    ability of our customers to obtain adequate third-party coverage
    and reimbursement for their purchases of our
    products.
    country-by-country
   19




---



##### 



Our
    future growth depends on increasing physician awareness of our
    TranS1 approach and our related products for appropriate
    treatment, intervention and referral.
    We
    have a limited operating history and have incurred losses since
    inception and we expect to incur increasing losses for the
    foreseeable future. We may never achieve or sustain
    profitability.
    We are
    in a highly competitive market segment, which is subject to
    rapid technological change. If our competitors are better able
    to develop and market products that are safer, more effective,
    less costly or otherwise more attractive than any products that
    we may develop, our ability to generate revenue will be reduced
    or eliminated.
    
    greater financial and human resources for product development,
    sales and marketing and patent litigation;
    significantly greater name recognition;
    established relationships with spine surgeons, customers and
    third-party payors;
    additional lines of products, and the ability to offer rebates
    or bundle products to offer greater discounts or incentives to
    gain a competitive advantage;
    established sales and marketing, and distribution
    networks; and
    greater experience in conducting research and development,
    manufacturing, clinical trials, preparing regulatory submissions
    and obtaining regulatory clearance or approval for products and
    marketing approved products. 20




---



##### 



Our
    failure to continue building effective sales and marketing
    capabilities for our products could significantly impair our
    ability to increase sales of our products.
    Our
    future success depends on our ability to develop, receive
    regulatory clearance or approval, and introduce new products or
    product enhancements that will be accepted by the market in a
    timely manner.
      
    properly identify and anticipate spine surgeon and patient needs;
    develop and introduce new products or product enhancements in a
    timely manner;
    avoid infringing upon the intellectual property rights of third
    parties;
    demonstrate, if required, the safety and efficacy of new
    products with data from preclinical studies and clinical trials;
    obtain the necessary regulatory clearances or approvals for new
    products or product enhancements;
    be fully FDA-compliant with marketing of new devices or modified
    products;
    provide adequate training to potential users of our products;
    receive adequate coverage and reimbursement for procedures
    performed with our products; and
    develop an effective and FDA-compliant, dedicated marketing and
    distribution network. 21




---



##### 



If
    clinical trials of our current or future product candidates do
    not produce results necessary to support regulatory clearance or
    approval in the United States or elsewhere, we will be unable to
    commercialize these products.
    
    the FDA, institutional review boards or other regulatory
    authorities do not approve a clinical study protocol, force us
    to modify a previously approved protocol, or place a clinical
    study on hold;
    patients do not enroll in, or enroll at the expected rate, or
    complete a clinical study;
    patients or investigators do not comply with study protocols;
    patients do not return for post-treatment
    follow-up at
    the expected rate;
    patients experience serious or unexpected adverse side effects
    for a variety of reasons that may or may not be related to our
    products such as the advanced stage of co-morbidities that may
    exist at the time of treatment, causing a clinical study to be
    put on hold;
    sites participating in an ongoing clinical study may withdraw,
    requiring us to engage new sites;
    difficulties or delays associated with bringing additional
    clinical sites on-line;
    third-party clinical investigators decline to participate in our
    clinical studies, do not perform the clinical studies on the
    anticipated schedule or consistent with the investigator
    agreement, clinical study protocol, good clinical practices, and
    other FDA and Institutional Review Board requirements;
    third-party organizations do not perform data collection and
    analysis in a timely or accurate manner;
    regulatory inspections of our clinical studies require us to
    undertake corrective action or suspend or terminate our clinical
    studies;
    changes in U.S. federal, state, or foreign governmental
    statutes, regulations or policies;
    interim results are inconclusive or unfavorable as to immediate
    and long-term safety or efficacy; or
    the study design is inadequate to demonstrate safety and
    efficacy.  and/or
 22




---



##### 



Our
    international operations subject us to certain operating risks,
    which could adversely impact our net sales, results of
    operations and financial condition.
      
    the imposition of additional U.S. and foreign governmental
    controls or regulations;
    the imposition of costly and lengthy new export licensing
    requirements;
    the imposition of U.S. or international sanctions against a
    country, company, person or entity with whom we do business that
    would restrict or prohibit continued business with the
    sanctioned country, company, person or entity;
    economic instability;
    a shortage of high-quality sales people and distributors;
    changes in third-party reimbursement policies that may require
    some of the patients who receive our products to directly absorb
    medical costs or that may necessitate the reduction of the
    selling prices of our products;
    changes in duties and tariffs, license obligations and other
    non-tariff barriers to trade;
    the imposition of new trade restrictions;
    the imposition of restrictions on the activities of foreign
    agents, representatives and distributors;
    scrutiny of foreign tax authorities which could result in
    significant fines, penalties and additional taxes being imposed
    on us;
    pricing pressure that we may experience internationally;
    laws and business practices favoring local companies;
    longer payment cycles;
    difficulties in maintaining consistency with our internal
    guidelines;
    difficulties in enforcing agreements and collecting receivables
    through certain foreign legal systems; and
    difficulties in enforcing or defending intellectual property
    rights.   23




---



##### 



The
    use, misuse or off-label use of our products may harm our image
    in the marketplace or result in injuries that lead to product
    liability suits, which could be costly to our business or result
    in FDA sanctions if we are deemed to have engaged in such
    promotion.
    We
    purchase some of the key components of our products from single
    suppliers. The loss of these suppliers could prevent or delay
    shipments of our products or delay our clinical trials or
    otherwise adversely affect our business.
     24




---



##### 



We
    depend on our officers and other key employees, and if we are
    not able to retain and motivate them or recruit additional
    qualified personnel, our business will suffer.
    If we
    fail to properly manage our anticipated growth, our business
    could suffer.
        If we
    need additional funding, we may be unable to raise capital when
    needed, which would force us to delay, reduce, eliminate or
    abandon our commercialization efforts or product development
    programs.
    
    expand the commercialization of our products;
    fund our operations and clinical trials;
    continue our research and development;
    defend, in litigation or otherwise, any claims that we infringe
    third-party patents or other intellectual property rights;
    address FDA or other governmental, legal/enforcement actions and
    remediate underlying problems
    commercialize our new products, if any such products receive
    regulatory clearance or approval for commercial sale; and
    acquire companies and in-license products or intellectual
    property. 25




---



##### 




    market acceptance of our products;
    the scope, rate of progress and cost of our clinical trials;
    the cost of our research and development activities;
    the cost of filing and prosecuting patent applications and
    defending and enforcing our patent and other intellectual
    property rights;
    the cost of defending, in litigation or otherwise, any claims
    that we infringe third-party patent or other intellectual
    property rights;
    the cost and timing of additional regulatory clearances or
    approvals;
    the cost and timing of establishing additional sales, marketing
    and distribution capabilities;
    the effect of competing technological and market
    developments; and
    the extent to which we acquire or invest in businesses, products
    and technologies, although we currently have no commitments or
    agreements relating to any of these types of transactions.      If we
    choose to acquire new businesses, products or technologies, we
    may experience difficulty in the identification or integration
    of any such acquisition, and our business may
    suffer.
    Consolidation
    in the healthcare industry could lead to demands for price
    concessions or to the exclusion of some suppliers from certain
    of our markets, which could have an adverse effect on our
    business, financial condition or results of
    operations.
   26




---



##### 



We
    face the risk of product liability or other claims and may not
    be able to obtain sufficient insurance coverage, if at
    all.
          If our
    independent contract manufacturers fail to timely deliver to us
    sufficient quantities of some of our products and components in
    a timely manner, our operations may be harmed.
    
    inadequate capacity of the manufacturers facilities;
    interruptions in access to certain process technologies; and
    reduced control over product availability, quality, delivery
    schedules, manufacturing yields and costs. 27




---



##### 



We
    operate at a single location. Any disruption in this facility or
    any inability to ship a sufficient number of our products to
    meet demand could adversely affect our business and results of
    operations.
    We
    have minimal experience operating as a public company.
    Compliance with public company requirements will increase our
    costs and require additional management resources, and we still
    may fail to comply.
  Form 10-K. Form 10-K
 28




---



##### 



Risks
    Related to Regulatory Environment
  If we
    fail to maintain regulatory approvals and clearances, or are
    unable to obtain, or experience significant delays in obtaining,
    FDA clearances or approvals for our future products or product
    modifications, our ability to commercially distribute and market
    these products could suffer.
        Modifications
    to our marketed products may require new 510(k) clearances or
    PMA approvals, or may require us to cease marketing or recall
    the modified products until clearances or approvals are
    obtained.
   29




---



##### 



Clinical
    trials necessary to support a PMA application will be expensive
    and will require the enrollment of large numbers of patients,
    and suitable patients may be difficult to identify and recruit.
    Delays or failures in our clinical trials will prevent us from
    commercializing any modified or new products and will adversely
    affect our business, operating results and
    prospects.
    follow-up follow-up
  and/or follow-up
  If the
    third parties on which we rely to conduct our clinical trials
    and to assist us with pre-clinical development do not perform as
    contractually required or expected, we may not be able to obtain
    regulatory clearance or approval for or commercialize our
    products.
   30




---



##### 



Even
    if our products are approved by regulatory authorities, if we or
    our suppliers fail to comply with ongoing FDA or other foreign
    regulatory authority requirements, or if we experience
    unanticipated problems with our products, these products could
    be subject to restrictions or withdrawal from the
    market.
    
    warning letters or untitled letters;
    fines and civil penalties;
    unanticipated expenditures to address or defend such actions;
    delays in clearing or approving, or refusal to clear or approve,
    our products;
    withdrawal or suspension of approval of our products or those of
    our third-party suppliers by the FDA or other regulatory bodies;
    product recall or seizure;
    orders for physician notification or device repair, replacement
    or refund;
    interruption of production;
    operating restrictions;
    injunctions; and
    criminal prosecution.       31




---



##### 



We may
    be subject to or otherwise affected by federal and state
    healthcare laws, including fraud and abuse and health
    information privacy and security laws, and could face
    substantial penalties if we are unable to fully comply with such
    laws.
    
    the federal Anti-Kickback Law, which constrains our marketing
    practices and those of our independent sales agents and
    distributors, educational programs, pricing policies, and
    relationships with healthcare providers, by prohibiting, among
    other things, soliciting, receiving, offering or providing
    remuneration, intended to induce the purchase or recommendation
    of an item or service reimbursable under a federal healthcare
    program (such as the Medicare or Medicaid programs);
    federal false claims laws which prohibit, among other things,
    knowingly presenting, or causing to be presented, claims for
    payment from Medicare, Medicaid, or other third-party payors
    that are false or fraudulent;
    the federal Health Insurance Portability and Accountability Act
    of 1996, or HIPAA, and its implementing regulations, which
    created federal criminal laws that prohibit executing a scheme
    to defraud any healthcare benefit program or making false
    statements relating to healthcare matters and which also imposes
    certain regulatory and contractual requirements regarding the
    privacy, security and transmission of individually identifiable
    health information; and
    state laws analogous to each of the above federal laws, such as
    anti-kickback and false claims laws that may apply to items or
    services reimbursed by any third-party payor, including
    commercial insurers, and state laws governing the privacy of
    certain health information, many of which differ from each other
    in significant ways and often are not preempted by HIPAA, thus
    complicating compliance efforts.  and/or
 32




---



##### 



Risks
    Related to Our Intellectual Property
  Our
    ability to protect our intellectual property and proprietary
    technology through patents and other means is
    uncertain.
        Any
    lawsuit, whether initiated by us to enforce our intellectual
    property rights or by a third party against us alleging
    infringement, may cause us to expend significant financial and
    other resources, and may divert our attention from our business
    and adversely affect our business, operating results and
    prospects.
     33




---



##### 



and/or
  
    pay damages, including, but not limited to, treble damages and
    attorneys fees, which may be substantial;
    cease the development, manufacture, use and sale of products
    that infringe the patent rights of others, through a
    court-imposed sanction called an injunction;
    expend significant resources to redesign our technology so that
    it does not infringe others patent rights, or develop or
    acquire non-infringing intellectual property, which may not be
    possible;
    discontinue manufacturing or other processes incorporating
    infringing technology; or
    obtain licenses to the infringed intellectual property, which
    may not be available to us on acceptable terms, or at all.    Risks
    Related to our Common Stock
  A sale
    of a substantial number of shares of our common stock may cause
    the price of our common stock to decline.
   34




---



##### 



lock-ups lock-up lock-up lock-up lock-up lock-up
  Our
    directors, officers and principal stockholders have significant
    voting power and may take actions that may not be in the best
    interests of our other stockholders.
    If
    securities or industry analysts do not publish research or
    reports about our business, if they change their recommendations
    regarding our stock adversely or if our operating results do not
    meet their expectations, our stock price and trading volume
    could decline.
    Volatility
    in the stock price of other companies may contribute to
    volatility in our stock price.
    Our
    amended and restated certificate of incorporation, amended and
    restated bylaws and Delaware law contain provisions that could
    discourage a takeover.
   35




---



##### 




    a classified board so that only one of the three classes of
    directors on our board of directors is elected each year;
    procedures for advance notification of stockholder director
    nominations and proposals;
    the ability of our board of directors to amend our bylaws
    without stockholder approval;
    a supermajority stockholder vote requirement for amending
    certain provisions of our amended and restated certificate of
    incorporation and our amended and restated bylaws; and
    the ability of our board of directors to issue up to
    5,000,000 shares of preferred stock without stockholder
    approval upon the terms and conditions and with the rights,
    privileges and preferences as our board of directors may
    determine.    Item 1B.
    Unresolved
    Staff Comments.    Item 2.
    Properties.    Item 3.
    Legal
    Proceedings.    Item 4.
    Submission
    of Matters to a Vote of Security Holders.     36




---



##### 



PART II  Item 5.
    Market
    for the Registrants Common Equity, Related Stockholder
    Matters and Issuer Purchases of Equity Securities  Price of
    Common Stock
    Price RangeHigh


LowFiscal 2007:Fourth Quarter (from October 17, 2007)

$
26.48


$
15.83       Uses of
    Proceeds from Sale of Registered Securities
  Form S-1 No. 333-144802), Form S-1 No. 333-146753),
       37




---



##### 



Dividend
    Policy
    Securities
    Authorized For Issuance Under Equity Compensation
    Plans
  (c)Number of Securities(a)


(b)


Remaining AvailableNumber of


Weighted-


for Future IssuanceSecurities to be


Average Exercise


Under EquityIssued Upon Exercise


Price of


Compensation Plansof Outstanding


Outstanding


(Excluding SecuritiesOptions, Warrants


Options, Warrants


Reflected in Columnand Rights


and Rights


(a)Plan categoryEquity compensation plans approved by security holders


2,320,281


$
3.22



1,133,057Equity compensation plans not approved by security holders










Total


2,320,281


$
3.22



1,133,057  38




---



##### 



Stock
    Price Performance Graph
    COMPARISON
    OF CUMULATIVE TOTAL RETURN
  
   The material in the above performance graph does not
    constitute soliciting material and should not be deemed filed or
    incorporated by reference into any other Company filing, whether
    under the Securities Act of 1933, as amended, or the Securities
    Exchange Act of 1934, as amended, whether made on, before or
    after the date of this report and irrespective of any general
    incorporation language in such filing, except to the extent we
    specifically incorporate this performance graph by reference
    therein.
 39




---



##### 



Item 6.
    Selected
    Financial Data.    Years Ended December 31,2007


2006


2005


2004


2003(In thousands, except share data)Statements of Operations Data:Revenue

$
16,473


$
5,812


$
1,469


$



$
Cost of revenue


3,042



1,580



386







Gross profit


13,431



4,232



1,083







Operating expensesResearch and development


4,785



4,246



2,444



1,758



1,620Sales and marketing


15,706



9,288



2,635



746



163General and administrative


2,901



1,166



1,293



1,117



927Total operating expenses


23,392



14,700



6,372



3,621



2,710Operating loss


(9,961
)


(10,468
)


(5,289
)


(3,621
)


(2,710
)Interest income


1,384



858



264



150



86Other income (expense)






131



(17
)






Net loss

$
(8,577
)

$
(9,479
)

$
(5,042
)

$
(3,471
)

$
(2,624
)Net loss per common share  basic and diluted

$
(1.46
)

$
(3.91
)

$
(2.25
)

$
(1.63
)

$
(1.28
)Weighted average common shares outstanding  basic and
    diluted


5,872,008



2,423,223



2,243,018



2,127,855



2,046,753   December 31,2007


2006


2005


2004


2003Balance Sheet Data:Cash, cash equivalents and short-term investments

$
93,921


$
14,962


$
25,994


$
6,708


$
10,283Working capital


98,351



17,448



26,696



6,674



10,193Total assets


102,856



20,004



28,013



7,139



10,461Preferred stock






40,089



40,089



14,544



14,544Common stock


2















Additional paid in capital


130,325



820



219



147



141Total stockholders equity/(deficit)


99,439



(21,529
)


(12,654
)


(7,680
)


(4,215
)  40




---



##### 



Item 7.
    Managements
    Discussion and Analysis of Financial Condition and Results of
    Operations    Overview
    start-up
        Financial
    Operations
  Revenue
   41




---



##### 



Cost of
    Revenue
    Research
    and Development
    Sales and
    Marketing
    General
    and Administrative
    Interest
    Income
    Results
    of Operations
  Comparison
    of the Years Ended December 31, 2007, 2006 and
    2005
  Revenue.
 42




---



##### 



Cost of Revenue.
  Research and Development.
  Sales and Marketing.
  General and Administrative.
 43




---



##### 



Other and Interest Income (Expense).
  Liquidity
    and Capital Resources
  Sources
    of Liquidity
          Cash
    Flows
       44




---



##### 



Operating
    Capital and Capital Expenditure Requirements
    Contractual
    Obligations
    Payments Due by YearLessThan


1-3


4-5


After 5Contractual Obligations

Total


1 Year


Years


Years


YearsOperating leases(1)

$
411


$
157


$
254


$



$
     (1)
    
    We rent office space under an operating lease which expires in
    2010.    Off-Balance
    Sheet Arrangements
    Critical
    Accounting Policies and Estimates
      Revenue Recognition.
 45




---



##### 



Accounts Receivable and Allowances.
  Inventory. first-in,
  Accounting for Income Taxes.
  Stock-Based Compensation.
 46




---



##### 



Recent
    Accounting Pronouncements
  New
    Accounting Standards
        Item 7A.
    Quantitative
    and Qualitative Disclosures About Market Risk      Item 8.
    Financial
    Statements and Supplementary Data.    Item 9.
    Changes
    in and Disagreements with Accountants on Accounting and
    Financial Disclosure.    Item 9A.
    Controls
    and Procedures  Evaluation
    of Disclosure Controls and Procedures
  Rules 13a-15(e) 15d-15(e)
 47




---



##### 



Changes
    in Internal Control over Financial Reporting
  Rules 13a-15(f) 15d-15(f)
  Item 9B.
    Other
    Information.    PART III  Item 10.
    Directors,
    Executive Officers and Corporate Governance.    Item 11.
    Executive
    Compensation.      Item 12.
    Security
    Ownership of Certain Beneficial Owners and Management and
    Related Stockholder Matters.    Item 13.
    Certain
    Relationships and Related Transactions, and Director
    Independence.    Item 14.
    Principal
    Accounting Fees and Services.   48




---



##### 



PART IV  Item 15.
    Exhibits,
    Financial Statement Schedules.      PageReport of Independent Registered Public Accounting Firm


52Balance Sheets


53Statements of Operations


54Statements of Stockholders Equity (Deficit)


55Statements of Cash Flows


56Notes to Financial Statements


57         Form 10-K
 49




---



##### 



SIGNATURES    TranS1 Inc.Date: March 25, 2008

By: /s/  Richard
    RandallRichard
    Randall
    President and Chief Executive OfficerDate: March 25, 2008

By: /s/  
    Michael LuetkemeyerMichael
    Luetkemeyer
    Chief Financial Officer   POWER OF
    ATTORNEY
  Form 10-K,
    Signature

Title

Date/s/  Richard
    RandallRichard
    Randall

President and Chief Executive Officer (Principal Executive
    Officer)

March 25, 2008/s/  Michael
    LuetkemeyerMichael
    Luetkemeyer

Chief Financial Officer
    (Principal Financial and Accounting Officer)

March 25, 2008/s/  Jonathan
    OsgoodJonathan
    Osgood

Director

March 25, 2008/s/  Mitchell
    DannMitchell
    Dann

Director

March 25, 2008/s/  James
    ShapiroJames
    Shapiro

Director

March 25, 2008/s/  Michael
    CarusiMichael
    Carusi

Director

March 25, 2008/s/  Joseph
    SlatteryJoseph
    Slattery

Director

March 25, 2008  50




---



##### 



TranS1
    Inc.
  Index to
    Financial Statements
  PageReport of Independent Registered Public Accounting Firm


52Balance Sheets


53Statements of Operations


54Statements of Stockholders Equity (Deficit)


55Statements of Cash Flows


56Notes to Financial Statements


57  51




---



##### 



Report of
    Independent Registered Public Accounting Firm            52




---



##### 



TranS1
    Inc.



Balance
    Sheets  December 31,2007


2006(In thousands, except share amounts)ASSETSCurrent assets:Cash and cash equivalents

$
64,676


$
5,034Short-term investments


29,245



9,928Accounts receivable, net


3,225



1,620Inventory


4,025



2,080Prepaid expenses and other assets


597



230Total current assets


101,768



18,892Property and equipment, net


1,088



1,112Total assets

$
102,856


$
20,004LIABILITIES AND STOCKHOLDERS EQUITY (DEFICIT)Current liabilities:Accounts payable

$
1,631


$
843Accrued expenses


1,786



601Total current liabilities


3,417



1,444Preferred Stock:Series A convertible preferred stock, $0.0001 par
    value; zero and 1,125,000 shares authorized, issued and
    outstanding at December 31, 2007 and 2006, respectively






956Series AA convertible preferred stock, $0.0001 par
    value; zero and 1,260,000 shares authorized and zero and
    1,259,999 shares issued and outstanding at
    December 31, 2007 and 2006, respectively






1,694Series B convertible preferred stock, $0.0001 par
    value; zero and 4,909,091 shares authorized and zero and
    4,909,082 shares issued and outstanding at
    December 31, 2007 and 2006, respectively






11,894Series C convertible preferred stock, $0.0001 par
    value; zero and 3,499,091 shares authorized and zero and
    3,499,084 shares issued and outstanding at
    December 31, 2007 and 2006, respectively






25,545Commitments (Note 5)Stockholders equity (deficit):Common stock, $0.0001 par value; 75,000,000 and 17,100
    000 shares authorized at December 31, 2007 and 2006,
    respectively; 19,843,941 and 2,435,484 shares issued and
    outstanding at December 31, 2007 and 2006, respectively


2



Additional paid-in capital


130,325



820Notes receivable for common stock






(38
)Accumulated deficit


(30,888
)


(22,311
)Total stockholders equity (deficit)


99,439



(21,529
)Total liabilities and stockholders equity (deficit)

$
102,856


$
20,004    53




---



##### 



TranS1
    Inc.



Statements
    of Operations  Year Ended December 31,2007


2006


2005(In thousands, except per share amounts)Revenue

$
16,473


$
5,812


$
1,469Cost of revenue


3,042



1,580



386Gross profit


13,431



4,232



1,083Operating expenses:Research and development


4,785



4,246



2,444Sales and marketing


15,706



9,288



2,635General and administrative


2,901



1,166



1,293Total operating expenses


23,392



14,700



6,372Operating loss


(9,961
)


(10,468
)


(5,289
)Interest income


1,384



858



264Other income (expense)






131



(17
)Net loss

$
(8,577
)

$
(9,479
)

$
(5,042
)Net loss per common share  basic and diluted

$
(1.46
)

$
(3.91
)

$
(2.25
)Weighted average common shares outstanding  basic and
    diluted


5,872



2,423



2,243    54




---



##### 



TranS1
    Inc.



Statements
    of Stockholders Equity (Deficit)  Additional








TotalCommon Stock


Paid-In


Notes


Accumulated


StockholdersNumber


Amount


Capital


Receivable


Deficit


Equity (Deficit)(In thousands, except share data)Balance at December 31, 2004


2,148,035


$



$
148


$
(38
)

$
(7,790
)

$
(7,680
)Issuance of common stock from exercised options


263,738







71



(3
)






68Net loss


















(5,042
)


(5,042
)Balance at December 31, 2005


2,411,773







219



(41
)


(12,832
)


(12,654
)Issuance of common stock from exercised options


23,711







2



3







5Stock-based compensation










599











599Net loss


















(9,479
)


(9,479
)Balance at December 31, 2006


2,435,484







820



(38
)


(22,311
)


(21,529
)Issuance of common stock from exercised options


290,292







123











123Issuance of common stock from initial public offering


6,325,000



1



86,658











86,659Conversion of preferred stock to common stock


10,793,165



1



40,088











40,089Stock-based compensation










2,636











2,636Repayment of note receivable














38







38Net loss


















(8,577
)


(8,577
)Balance at December 31, 2007


19,843,941


$
2


$
130,325


$



$
(30,888
)

$
99,439    55




---



##### 



TranS1
    Inc.



Statements
    of Cash Flows  Year Ended December 31,2007


2006


2005(In thousands)Cash flows from operating activities:Net loss

$
(8,577
)

$
(9,479
)

$
(5,042
)Adjustments to reconcile net loss to net cash used in operating
    activities:Depreciation


540



237



106Stock-based compensation


2,636



599



Allowance for excess and obsolete inventory


306



350



57Provision for bad debts


95



64



Disposal of fixed assets










17Changes in operating assets and liabilities:Increase in accounts receivable


(1,700
)


(1,120
)


(564
)Increase in inventory


(2,251
)


(1,846
)


(457
)Increase in prepaid expenses


(367
)


(99
)


(76
)Increase in accounts payable


788



508



280Increase in accrued liabilities


1,185



358



23Net cash used in operating activities


(7,345
)


(10,428
)


(5,656
)Cash flows from investing activities:Purchase of property and equipment


(516
)


(609
)


(672
)Purchases of short-term investments


(30,687
)


(13,925
)


(5,449
)Sales of short-term investments


11,370



9,447



Net cash used in investing activities


(19,833
)


(5,087
)


(6,121
)Cash flows from financing activities:Proceeds from issuance of convertible preferred stock, net










25,545Proceeds from issuance of common stock


86,820



5



68Net cash provided by financing activities


86,820



5



25,613Net increase (decrease) in cash and cash equivalents


59,642



(15,510
)


13,836Cash and cash equivalents, beginning of period


5,034



20,544



6,708Cash and cash equivalents, end of period

$
64,676


$
5,034


$
20,544Supplemental disclosure of noncash financing activities:Conversion of preferred stock to common stock

$
40,089    56




---



##### 



TranS1
    Inc.



Notes to
    Financial Statements  1.
    Organization      2.
    Summary
    of Significant Accounting Policies  Basis
    of Presentation
      Use of
    Estimates
    Cash
    and Cash Equivalents
   57




---



##### 



TranS1
    Inc.
  Notes to
    Financial Statements  (Continued)
  Investments
    December 31,2007


2006(In thousands)Commercial paper

$
14,117


$
3,622Corporate debt securities


8,695



4,113Asset backed securities


6,433



400U.S. government securities






1,793Total short-term investments

$
29,245


$
9,928   Fair
    Value of Financial Instruments
    Accounts
    Receivable
    December 31,2007


2006(In thousands)Gross accounts receivable

$
3,335


$
1,649Allowance for uncollectible accounts


(110
)


(29
)Total accounts receivable, net

$
3,225


$
1,620   Concentration
    of Credit Risk and Significant Customers
       58




---



##### 



TranS1
    Inc.
  Notes to
    Financial Statements  (Continued)
  Inventories
    December 31,2007


2006(In thousands)Raw materials

$
212


$
147Work-in-process


2,189



1,080Finished goods


1,624



853Total inventories

$
4,025


$
2,080   first-in,
  Property
    and Equipment
      Furniture and fixtures

5-10 yearsEquipment

3-5 yearsOther depreciable assets

2-10 yearsLeasehold improvements

Lesser of estimated useful life or lease term   Revenue
    Recognition
  and/or
 59




---



##### 



TranS1
    Inc.
  Notes to
    Financial Statements  (Continued)
    Shipping
    and Handling Costs
    Sales
    and Marketing Expenses
    Research
    and Development Expenses
    Patent
    Costs
    Income
    Taxes
    Stock-Based
    Compensation
  Accounting for Stock Issued to
    Employees Accounting for
    Stock-Based Compensation
    Share-Based Payment
 60




---



##### 



TranS1
    Inc.
  Notes to
    Financial Statements  (Continued)
    No. 96-18, Accounting for Equity Instruments That Are Issued to Other
    Than Employees for Acquiring, or in Conjunction with Selling
    Goods or Services
  Net
    Loss Per Common Share
      Year Ended December 31,2007


2006


2005Convertible preferred stock






10,793,165



10,793,165Weighted average stock options outstanding


1,928,495



1,213,938



985,990   Segment
    and Geographic Reporting
   61




---



##### 



TranS1
    Inc.
  Notes to
    Financial Statements  (Continued)
    Year Ended December 31,2007


2006


2005(In thousands)United States

$
15,085


$
5,453


$
1,469Europe


1,183



359



Other


205







$
16,473


$
5,812


$
1,469   Recently
    Issued Accounting Standards
  Fair Value
    Measurements
  The Fair
    Value Option for Financial Assets and Financial
    Liabilities  Including an amendment of FASB Statement
    No. 115
    3.
    Property
    and Equipment    December 31,2007


2006(In thousands)Furniture and fixtures

$
139


$
115Equipment


1,136



682Computer software


300



158Leasehold improvements


330



314Tools


73



73Construction in process


23



1432,001



1,485Less: accumulated depreciation and amortization


(913
)


(373
)$
1,088


$
1,112  62




---



##### 



TranS1
    Inc.
  Notes to
    Financial Statements  (Continued)
    4.
    Accrued
    Expenses    December 31,2007


2006(In thousands)Commissions

$
561


$
209Bonus


426



167Legal and professional fees


277



50Travel & entertainment


127



Vacation


95



73Clinical


94



69Consulting


59



13Other


147



20Total accrued expenses

$
1,786


$
601   5.
    Lease
    Obligations      Year ending December 31,2008

$
1572009


1612010


932011


2012 and after


$
411     6.
    Stockholders
    Equity    Preferred
    Stock
   63




---



##### 



TranS1
    Inc.
  Notes to
    Financial Statements  (Continued)
        Common
    Stock
    Dividends
    Voting
    Liquidation
      7.
    Stock
    Incentive Plans and Stock-Based Compensation  2007
    Employee Stock Purchase Plan
   64




---



##### 



TranS1
    Inc.
  Notes to
    Financial Statements  (Continued)
  Form S-1,
      2000
    and 2007 Stock Incentive Plans
   65




---



##### 



TranS1
    Inc.
  Notes to
    Financial Statements  (Continued)
    Number


PriceOutstanding as of December 31, 2004


1,033,226


$
0.27Options granted


416,574



0.29Options exercised


(263,738
)


0.28Options forfeited






Outstanding as of December 31, 2005


1,186,062



0.27Options granted


735,373



1.11Options exercised


(30,273
)


0.21Options forfeited


(49,486
)


0.28Outstanding as of December 31, 2006


1,841,676



0.59Options granted


843,157



7.77Options exercised


(290,292
)


0.40Options forfeited


(74,260
)


0.46Outstanding as of December 31, 2007


2,320,281


$
3.22     Weighted


WeightedAverage


Average


Number ofNumber


Contractual


Exercise


OptionsRange of Exercise Prices

Outstanding


Life (Years)


Price


Exercisable$ 0.11  $0.28


803,351



5.7


$
0.22



723,095$ 1.11  $2.38


770,410



8.9



1.23



305,135$ 5.56  $7.78


497,520



9.4



5.75



9,145$12.22


189,000



9.7



12.22



$19.66


60,000



9.9



19.66



18,1252,320,281



8.0


$
3.22



1,055,500     Stock-Based
    Compensation for Non-employees
   66




---



##### 



TranS1
    Inc.
  Notes to
    Financial Statements  (Continued)
      Employee
    Stock-Based Compensation on or Subsequent to January 1,
    2006
      Expected Life.
  Volatility.
  Risk-Free Interest Rate.
  Dividend Yield.
  Forfeitures.
 67




---



##### 



TranS1
    Inc.
  Notes to
    Financial Statements  (Continued)
      8.
    Income
    Taxes      2007


2006


2005(In thousands)Deferred tax assetsDomestic net operating loss carryforwards

$
8,615


$
7,584


$
4,761Inventory


177







Fixed assets


84







Other


80



3



3Research and development credit


568



624



402Total deferred tax assets


9,524



8,211



5,166Valuation allowance for deferred assets


(9,524
)


(8,121
)


(5,137
)Deferred tax assets






90



29Deferred tax liabilitiesFixed assets






90



29Total deferred tax liabilities






90



29Net deferred tax assets (liabilities)

$



$



$
      68




---



##### 



TranS1
    Inc.
  Notes to
    Financial Statements  (Continued)
    2007


2006


2005% of





% of





% ofAmount


Net Loss


Amount


Net Loss


Amount


Net Loss(In thousands)Tax at statutory rate

$
(3,002
)


35.0
%

$
(3,318
)


35.0
%

$
(1,765
)


35.0
%State taxes


(394
)


4.6
%


(213
)


2.2
%


(226
)


4.5
%Non deductible items


998



(11.6
)%


270



(2.8
)%


71



(1.4
)%Other


53



(0.6
)%


421



(4.3
)%






R&D credits


(115
)


1.3
%


(144
)


1.5
%


(97
)


1.9
%Change in valuation allowance


2,460



(28.7
)%


2,984



(31.5
)%


2,017



(40.0
)%Total

$




0.0
%

$




0.0
%

$




0.0
%     Balance at January 1, 2007

$
1,057Gross increases related to current period tax positions


57Balance at December 31, 2007

$
1,114    69




---



##### 



TranS1
    Inc.
  Notes to
    Financial Statements  (Continued)
  9.
    Quarterly
    Data (Unaudited)    Year Ended December 31, 2007First


Second


Third


FourthQuarter


Quarter


Quarter


QuarterTotal revenues

$
3,115


$
4,072


$
4,327


$
4,959Gross profit


2,525



3,203



3,573



4,130Total operating expenses


4,404



5,794



5,912



7,283Net loss

$
(1,697
)

$
(2,430
)

$
(2,214
)

$
(2,237
)Basic and diluted net loss per common share

$
(0.69
)

$
(0.98
)

$
(0.87
)

$
(0.14
)   Year Ended December 31, 2006First


Second


Third


FourthQuarter


Quarter


Quarter


QuarterTotal revenues

$
968


$
1,193


$
1,367


$
2,284Gross profit


783



763



1,033



1,652Total operating expenses


2,887



3,780



3,686



4,346Net loss

$
(1,833
)

$
(2,760
)

$
(2,405
)

$
(2,467
)Basic and diluted net loss per common share

$
(0.76
)

$
(1.14
)

$
(0.99
)

$
(1.01
)  70




---



##### 



TRANS1
    INC.
    SCHEDULE II
    VALUATION AND QUALIFYING ACCOUNTS
    FOR THE YEARS ENDED DECEMBER 31, 2007, 2006 AND 2005
  Balance at








Balance atBeginning








End ofof Period


Additions(1)


Deductions(2)


Period(In thousands)Accounts Receivable Reserve:Year ended December 31, 2007

$
29


$
95


$
14


$
110Year ended December 31, 2006






64



35



29Year ended December 31, 2005














   Balance at








Balance atBeginning








End ofof Period


Additions(3)


Deductions(4)


PeriodInventory Reserve:Year ended December 31, 2007

$
57


$
306


$
68


$
295Year ended December 31, 2006


10



350



303



57Year ended December 31, 2005






57



47



10   Balance at








Balance atBeginning








End ofof Period


Additions


Deductions(5)


PeriodValuation Allowance for Deferred Tax Assets:Year ended December 31, 2007

$
8,121


$
2,460


$
1,057


$
9,524Year ended December 31, 2006


5,137



2,984







8,121Year ended December 31, 2005


3,120



2,017







5,137     (1)
    
    Amount represents customer balances deemed uncollectible.(2)
    
    Uncollectible accounts written-off.(3)
    
    Amount represents excess and obsolete reserve recorded to cost
    of sales.(4)
    
    Excess and obsolete inventory written-off against reserve.(5)
    
    Adjustment for the adoption of FIN 48 on January 1,
    2007. 71




---



##### 



EXHIBIT INDEX
  ExhibitNo.

Description3
.1

Amended and Restated Certificate of Incorporation of TranS1 Inc.
    (incorporated by reference to Exhibit 3.2 to the
    Registration Statement on
    Form S-1,
    as amended (File
    No. 333-144802),
    and as declared effective on October 16, 2007).3
.2

Amended and Restated Bylaws of TranS1 Inc. (incorporated by
    reference to Exhibit 3.4 to the Registration Statement on
    Form S-1,
    as amended (File
    No. 333-144802),
    and as declared effective on October 16, 2007).4
.1

Specimen common stock certificate (incorporated by reference to
    Exhibit 4.1 to the Registration Statement on
    Form S-1,
    as amended (File
    No. 333-144802),
    and as declared effective on October 16, 2007).10
.1

Amended and Restated 2000 Stock Incentive Plan (incorporated by
    reference to Exhibit 10.1 to the Registration Statement on
    Form S-1,
    as amended (File
    No. 333-144802),
    and as declared effective on October 16, 2007).*10
.2

Form of Stock Option Agreement under Amended and Restated 2000
    Stock Incentive Plan (incorporated by reference to
    Exhibit 10.2 to the Registration Statement on
    Form S-1,
    as amended (File
    No. 333-144802),
    and as declared effective on October 16, 2007).*10
.3

2007 Stock Incentive Plan (incorporated by reference to
    Exhibit 10.3 to the Registration Statement on
    Form S-1,
    as amended (File
    No. 333-144802),
    and as declared effective on October 16, 2007).*10
.4

Form of Stock Option Agreement under 2007 Stock Incentive Plan
    (incorporated by reference to Exhibit 10.4 to the
    Registration Statement on
    Form S-1,
    as amended (File
    No. 333-144802),
    and as declared effective on October 16, 2007).*10
.5

2007 Employee Stock Purchase Plan (incorporated by reference to
    Exhibit 10.5 to the Registration Statement on
    Form S-1,
    as amended (File
    No. 333-144802),
    and as declared effective on October 16, 2007).*10
.6

Lease, dated March 16, 2005, between TranS1 Inc. and
    Ellmore Enterprises (incorporated by reference to
    Exhibit 10.6 to the Registration Statement on
    Form S-1,
    as amended (File
    No. 333-144802),
    and as declared effective on October 16, 2007).10
.7

Form of Indemnification Agreement (incorporated by reference to
    Exhibit 10.7 to the Registration Statement on
    Form S-1,
    as amended (File
    No. 333-144802),
    and as declared effective on October 16, 2007).10
.7.1

Schedule of Parties to Indemnification Agreement.**23
.1

Consent of Independent Registered Public Accounting Firm.**24
.1

Power of Attorney (included in the signature page).31
.1

Certification of Chief Executive Officer Pursuant to
    Rule 13a-14(a)
    / 15d-14(a) of the Securities Exchange Act of 1934.**31
.2

Certification of Chief Financial Officer Pursuant to
    Rule 13a-14(a)
    / 15d-14(a) of the Securities Exchange Act of 1934.**32
.1

Certification of Chief Executive Officer Pursuant to
    Rule 13a-14(b)
    / 15d-14(b) of the Securities Exchange Act of 1934 and
    18 U.S.C. Section 1350.**32
.2

Certification of Chief Financial Officer Pursuant to
    Rule 13a-14(b)
    / 15d-14(b) of the Securities Exchange Act of 1934 and
    18 U.S.C. Section 1350.**     *
    
    These exhibits are identified as management contracts or
    compensatory plans or arrangements of the Registrant pursuant to
    Item 15(a)(3) of Form
    10-K.**
    
    Filed herewith. 72